Statistics

Total Visits

Views
Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)45

Select a period of time:

Number of views in the range

Views
Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 1)24

Views

Views
January 20250
February 20250
March 202515
April 20258
May 20251
June 20250
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
Hong Kong6
United States2
Spain1
 

Top cities views

Views
Hong Kong6
Council Bluffs1
Pueblo1